Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Exenatide is an incretin mimetic with potential glucoregulatory activity in type 2 diabetes. This randomized, single‐blind, placebo‐controlled 6‐way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics. Of 40 randomized healthy subjects, 39 completed the study. On the placebo day, acetaminophen (1000 mg) was ingested and placebo injected subcutaneously at 0 hours. On exenatide days, acetaminophen was ingested at −1, 0, +1, +2, and +4 hours, relative to the 10 μg exenatide injected subcutaneously at 0 hours. With exenatide injection, mean plasma acetaminophen AUC0–12 h values were reduced by 11% to 24% (vs placebo). Peak plasma acetaminophen concentrations were similar for the −1‐hour and placebo groups and reduced by 37% to 56% at other times. The most frequent adverse events were generally mild to moderate nausea and vomiting. Exenatide treatment concurrent with or preceding acetaminophen ingestion slowed acetaminophen absorption but had minimal effect on the extent of absorption.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Co-administration of exenatide [13], lixisenatide [36], liraglutide [19], dulaglutide [32, 38] or semaglutide [27, 40] resulted in decreased Cmax and delayed tmax of acetaminophen (Table 3).”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [13]
In the citing paper
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [13]
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“This was true for both solid(13,18) and liquid(19) gastric emptying and for healthy subjects(17,18,20) as well as those with type 2 diabetes.(13) Slowing of gastric emptying by exenatide has also been examined.”
BackgroundResultPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065 · cited 1×
“Moreover, many available therapeutic agents have undesirable side effects, such as weight gain, hypoglycemia, and edema, which can discourage patient compliance and hence impede glycemic control.(3,4) Exenatide (exendin-4), currently under clinical evaluation for glycemic control in patients with type 2 diabetes, is a…”
BackgroundImprovement of Gastric Emptying in Diabetic Gastroparesis by Erythromycin: Preliminary Studies
Janssens, J., Peeters, T. L., Vantrappen, G., Tack, J., Urbain, J. L., De Roo, M., Muls, E., & Bouillon, R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221502 · Cited by 753
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552 · cited 1×
“Like GLP1, exenatide slowed gastric emptying in healthy subjects(12) and subjects with type 2 diabetes.(5) These previous studies formed the basis for the more extensive examination of exenatide’s effects on gastric emptying described here.”
ResultSelf-citation
Research works printed but not linked: 4
- 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
- Jodka C, 1998, Exendin‐4 potently stimulates gastric emptying in rats [abstract], Diabetes, 47, A403
- Soon D, 2004, Effect of exenatide on digoxin pharmacokinetics, Clin Exp Pharmacol Physiol., 31, A65
Cited by
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Self-citationLiraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C., Musi, N., DeFronzo, R. A., & Cersosimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157
“On the basis of the plasma acetaminophen levels, which closely reflect the liquid component of the meal (1), 58% of the glucose retained in the splanchnic area could be accounted for by slowing of gastric emptying.”
BackgroundResult
Metadata
- Authors
- Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M.
- Corresponding author
- Fineman, Mark
- ORCID
- Fineman, Mark
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-05
- Volume
- 45
- Issue
- 5
- Pages
- 570-577
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2001592873
- Cited by
- 82
- References
- 46
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 1 · 2012: 9
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- exenatide, exendin-4, paracetamol, drug-drug interactions, pharmacokinetics, oral drug absorption, subcutaneous administration, type 2 diabetes, glucoregulation, nausea and vomiting
- MeSH terms
- Exenatide, Acetaminophen, Administration, Oral, Adolescent, Adult, Aged, Drug Interactions, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Peptides, Venoms, Single-Blind Method, Cross-Over Studies, Analgesics, Non-Narcotic, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects. https://app.cochat.ai/papers/10.1177/0091270004274432
- The paper
- Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005). Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270004274432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.